DDW’s Megan Thomas speaks with Dr Maria-Magdalena Patru, Scientific Partner at Roche Diagnostics US, about how advances in Alzheimer’s disease (AD), particularly blood-based biomarkers (BBM), can enable earlier, more accurate, and accessible detection of the disease, supporting timely treatment and improved patient outcomes. 

MT: Why is improving AD diagnostics crucial for researchers trying to understand such a complex disease?

MP: Today, barriers to early and accurate diagnosis of AD exist across the globe, with up to 75% of people living with dementia doing so without a diagnosis. Those who have received a diagnosis waited, on average, 2.8 years after symptom onset to seek one and are usually diagnosed late, in dementia stage1.

Identifying the cause of cognitive impairment is important because AD, while being the major cause for these symptoms, is not the only one. With the availability of and future promise of more disease-specific therapies, identifying the pathology specific for the disease is key to offering patients appropriate therapy solutions. For example, currently, there are AD therapies that target the amyloid pathology. The availability of tests that can detect amyloid pathology in the early stages of the disease is crucial to a patient’s eligibility for treatment.

To address the growing strain that AD is putting on healthcare systems, it will be essential to diagnose it in early symptomatic disease stages (for instance, mild cognitive impairment and mild dementia) and treat those patients with amyloid targeting therapies before they transition to moderate or severe dementia. This can be achieved by providing testing tools for clinicians to identify disease-specific pathology and by increasing patients’ awareness and access to these tests.

MT: With nearly seven million people in the US affected by AD and cases expected to rise, how can better diagnostic tools help address this growing public health challenge?

MP: Blood testing as an indicator of developing AD, will be a huge step forward in the field of neuropathology. The development of a blood-based biomarker (BBM) test could play an important role in making timely and accurate diagnoses more accessible and to better monitor the effects of the rapidly developing disease modifying treatment for neurological diseases and dementia.

Blood-based AD tests have the potential to address the accessibility and invasiveness issues associated with current diagnostic methods. The current FDA-approved tests for AD (positron emission tomography (PET) scans, and cerebrospinal fluid (CSF) assays) are highly effective but also come with limitations.

When implemented in clinical practice for patients with cognitive symptoms, blood tests could have an important role in shaping and streamlining the diagnostic pathway and contributing to the timely identification of AD in the early disease stage. We envision blood tests to be part of a comprehensive and targeted diagnostic workup, reducing costs for the healthcare system by minimising expensive and invasive diagnostic procedures and by reducing unnecessary procedures for patients with low likelihood of amyloid pathology. Additional clinical utility studies are expected to demonstrate the positive impact on clinicians’ decisions and the benefit for patients.

BBM tests hold immense promise to facilitate efficient and accurate AD diagnosis, but their place in diagnostic workflows is still evolving. As a less invasive, time-effective, more accessible, and scalable modality, BBM tests could inform referrals from primary care settings and enable more efficient diagnostic processes. They also hold great potential for future applications, such as tracking disease progression and monitoring therapy efficacy.

However, BBM tests are unlikely to replace existing AD diagnostic methods entirely. CSF has the advantage of providing a better indicator of brain pathology than blood, as it is less prone to interference and protein degradation.2 Additionally, directly visualising the location and extent of amyloid/tau deposits with PET imaging is favoured by many neurology specialists. These established methods will likely persist as an additional confirmatory approach to support BBM test results when necessary. Reserving these more invasive and less accessible AD diagnostic methods for confirmatory testing could support more efficient patient care.

MT: Given the subtlety of early symptoms, what specific challenges do current diagnostic methods face in reliably detecting AD before significant cognitive decline occurs?

MP: In general, both amyloid PET imaging and fluid biomarker methods can detect changes in the abnormal proteins in the very early disease stage. However, there are differences in the performance of different assays/biomarkers/methods. Their clinical use is also influenced by their availability, patient/clinician preference, contraindications, invasiveness, and/or coverage. PET imaging offers clinicians the advantage of visualising and quantifying the amyloid and tau deposits, which constitute the hallmark AD pathologies. Still, it does have disadvantages when it comes to accessibility as it’s not widely available, it is costly, and it comes with a certain degree of invasiveness. CSF biomarker ratio assays, while also highly accurate, and comparable with amyloid PET in performance, are perceived as more invasive due to the need for a lumbar puncture procedure. In contrast, the invasiveness of blood tests is minimal – a blood draw is a much more routine procedure compared to a lumbar puncture, and accessibility of blood tests is significantly higher, especially when compared with that of the PET scans.

There are also challenges in developing accurate blood-based AD tests. Blood is a very different matrix than CSF and that comes also with differences in the sources and lower concentrations of these proteins, which require more sensitive and specific assays. To be implemented in clinical practice, blood tests are expected to have a similar or better performance than the CSF tests. Multiple studies show promising performance results but there is a need for more real-world data and for regulatory approval and coverage to increase access and utilisation of these tests. 

MT: Roche’s data suggests that a blood test can accurately identify amyloid pathology. What biomarkers are being measured, and how do they correlate with established gold-standard diagnostics like CSF analysis and PET imaging?

MP: Early disease-stage diagnosis will facilitate access to amyloid-targeting as well as other new disease-specific therapies as they become available. Currently, FDA-approved (cleared) tests such as the cerebrospinal fluid ratios which measure amyloid, phosphorylated tau 181 and total tau protein as well as the amyloid Positron Emission Tomography (PET) imaging can detect amyloid pathology. Due to their close correlation (90%), either can be used to qualify patients for the amyloid-targeting therapy in early disease stages (mild cognitive impairment and mild dementia). However, access to these tests is limited, and their invasiveness is higher compared to a blood draw.

The most promising BBMs are phosphorylated tau (pTau) proteins, including pTau217 and pTau181, which are highly correlated with the presence of amyloid pathology. In addition to these BBMs, research indicates that other markers of inflammation and neurodegeneration, such as glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), could also be applicable in AD care2. While these markers are not specific to AD pathology, they can provide valuable insight into disease staging and progression.

MT: How does the sensitivity and specificity of blood-based tests compare across AD symptomatic stages? 

MP: BBM hold significant promise in revolutionising the detection of AD. By providing a simpler alternative to the current standards for AD testing, it is hoped that blood tests will transform the diagnostic process by reducing the need for invasive and expensive diagnostic procedures and ensuring timely access to appropriate care and emerging therapies.

When comparing the sensitivity and specificity of blood-based tests in symptomatic patients across AD continuum (mild cognitive impairment-MCI, mild, moderate followed by severe dementia), it is crucial to ensure the tests can reliably detect patients in the early symptomatic stages of the disease, for example MCI and mild dementia. Early disease stage detection is essential, as patients transitioning into the moderate dementia stage will miss the opportunity for specific, amyloid-targeting treatment. Therefore, the blood tests should be sensitive enough to detect not just later, more severe disease, but initial, small changes associated with early symptomatic disease. Specificity is also important to ensure the results reflect AD pathology.

MT: How do FDA-cleared cerebrospinal fluid (CSF) biomarker tests measuring beta-amyloid and tau proteins support early AD diagnosis? 

MP: AD is characterised by the early changes in levels and accumulation of amyloid beta and tau proteins in plaques and tangles. These modifications can be viewed using PET imaging or measured with CSF ratio assays. The Elecsys Beta-Amyloid (1-42) CSF II and Elecsys Phospho‑Tau (181P) CSF assays accurately and reliably measure the beta‑Amyloid (1‑42) and Phospho‑Tau 181 concentrations in CSF in adult subjects being evaluated for AD and other causes of cognitive impairment. As changes in these biomarkers’ levels occur even before symptoms become apparent, the ratios can detect AD pathology in very early symptomatic disease stage.

MT: What steps is Roche taking to make its AD diagnostic tests more widely available?

MP: I believe that at Roche, one of our greatest strengths is the innovation on patients’ behalf. We develop biomarkers that can answer patients’ needs by translating the latest discoveries into accurate, well-validated tests that can be used reliably worldwide. Our platforms have a massive footprint – for example, we have more than 4,000 immunoassay instruments installed in the US, with more being added every day, making Roche assays broadly accessible and providing unrivalled capacity to deliver high medical value solutions to patients at scale. Additionally, our medical teams are routinely engaging with laboratorians and clinicians to discuss and increase their knowledge on the rapidly evolving AD diagnostics landscape.

Our diagnostics portfolio has the potential to streamline AD patient’s journey, improving speed and access toward a diagnosis, giving people with AD and their caregivers an answer for their symptoms and the opportunity to manage this disease better. We are committed to working with regulatory agencies to make our solutions widely available to the AD community as soon as possible.

MT: How is Roche contributing to the broader field of neurology through its work in AD diagnostics?

MP: Before the recent approval and introduction of biomarker tests and amyloid-targeting therapies, the field faced a critical lack of diagnostic tools and disease-specific treatment options. Identifying AD pathology with biomarker tests moves AD from a diagnosis of exclusion towards one of inclusion, increases diagnostic accuracy and qualifies patients for amyloid-targeting therapies shown to slow cognitive decline. These therapies are most effective in early-stage disease, so identifying patients in the initial symptomatic stages (such as mild cognitive impairment or mild dementia) is essential in ensuring that patients have a chance to receive timely treatment.

Roche Diagnostics has made valuable progress in the field thus far by developing accessible, scalable, and time-efficient tests: two Elecsys CSF-based ratio assays of three different AD-relevant biomarkers (pTau181/Amyloid beta42 and TotalTau/Abeta42) are currently cleared by the FDA and available to laboratories. These tests can detect amyloid pathology in early-stage symptomatic disease and aid clinical decisions. Additionally, Roche’s pTau181 and pTau217 plasma biomarker tests have received Breakthrough Device Designation, highlighting strides forward in developing blood-based AD biomarker assays and their potential for broadening access to timely and accurate diagnosis.

AD is a complex disease with multiple pathologies, so we must continue working to ensure that patients have the right test for their clinical needs, not just for now, but also for the future, when more therapies become available.

MT: How do you see the landscape of AD diagnostics evolving in the next five years, and what role will Roche play in driving these advancements?

MP: In AD, the field is evolving rapidly – there are constantly new and exciting discoveries that we consider in our development strategies as the pieces of this puzzle come together. The current availability of cerebrospinal fluid (CSF) and imaging biomarkers with their ability to detect amyloid pathology and qualify patients for amyloid targeting therapies has already transformed the way clinicians approach this disease. The patient pathway will be further streamlined once blood-based and digital biomarkers are validated, regulatory approved, and implemented in clinical practice.

Our next big challenge is optimising how these tools can be used together in both primary and specialty care settings to make diagnosis and treatment accessible for as many patients as possible. For example, in addition to clinical investigations and cognitive assessments, ruling out symptomatic patients with a low likelihood of AD pathology with triage testing in primary care and referring the ones with positive results for further confirmatory AD testing in specialty care could translate into a faster, timely AD diagnosis and treatment with increased probability of positive outcomes.

The field is also seeking new biomarkers, most probably to be used in combination, to aid in differentiating other pathologies, and addressing other clinical needs, such as disease progression in asymptomatic stages, therapy monitoring and identification of side effects.

As pharmaceutical companies also work to develop therapies targeting other specific pathologies (e.g., tau), the field is moving from the “one size fits all” concept closer to achieving the goal of a precision medicine approach. These are formative years in the AD biomarker landscape! When we can help patients get answers and provide routes to possible therapeutic options, it can really change lives.

More information can be found at www.diagnostics.roche.com

References
  1. Alzheimer’s Disease International
  2. Alawode DOT, Heslegrave AJ, Ashton NJ, et al. Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer’s disease. J Intern Med. 2021;290(3):583–601
Biography
Dr. Maria-Magdalena Patru, Roche Diagnostics US (Photograph courtesy of Roche Diagnostics)

Dr Maria-Magdalena Patru is an experienced physician-scientist, with over 15 years in the field and more than 11 years in the in-vitro diagnostics industry. Currently serving as the Scientific Partner for neurology at Roche Diagnostics US, she leads a team developing medical strategies for neurology biomarkers, primarily focusing on Alzheimer’s disease. Her background includes a medical degree, Laboratory Medicine training, a PhD in Microbiology and Immunology, a clinical laboratory fellowship, and extensive experience in medical and scientific affairs, particularly in IVD product development, validation, and clinical trials.